Cardiac and vascular effects of fingolimod: mechanistic basis and clinical implications.

Camm, John; Hla, Timothy; Bakshi, Rajesh; Brinkmann, Volker

Camm, John; Hla, Timothy; Bakshi, Rajesh; Brinkmann, Volker.

Affiliation

Camm J; Cardiovascular Sciences Research Centre, Division of Clinical Sciences, St George's, University of London, London, United Kingdom. Electronic address: jcamm@sgul.ac.uk.
Hla T; Center for Vascular Biology, Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, Cornell University, New York, NY.
Bakshi R; Novartis Pharma AG, Basel, Switzerland.
Brinkmann V; Novartis Pharma AG, Basel, Switzerland.

Am Heart J ; 168(5): 632-44, 2014 Nov.

Article in En | MEDLINE | ID: mdl-25440790

Subject(s)

Atrioventricular Node/drug effects; Heart Rate/drug effects; Immunosuppressive Agents/pharmacology; Propylene Glycols/pharmacology; Receptors, Lysosphingolipid/drug effects; Sphingosine/analogs & derivatives; Cardiovascular System/drug effects; Down-Regulation; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents/therapeutic use; Multiple Sclerosis/drug therapy; Propylene Glycols/therapeutic use; Receptors, Lysosphingolipid/agonists; Receptors, Lysosphingolipid/antagonists & inhibitors; Signal Transduction/drug effects; Sphingosine/pharmacology; Sphingosine/therapeutic use

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Propylene Glycols / Atrioventricular Node / Sphingosine / Receptors, Lysosphingolipid / Heart Rate / Immunosuppressive Agents Type of study: Guideline Limits: Humans Language: En Journal: Am Heart J Year: 2014 Type: Article

Fulltext

XML

PubMed Links

Search on Google